Your browser doesn't support javascript.
loading
In search of a new paradigm for protective immunity to TB.
Nunes-Alves, Cláudio; Booty, Matthew G; Carpenter, Stephen M; Jayaraman, Pushpa; Rothchild, Alissa C; Behar, Samuel M.
Affiliation
  • Nunes-Alves C; 1] Department of Microbiology and Physiological Systems, University of Massachusetts Medical School, Worcester, Massachusetts 01655, USA. [2] Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, 4710-057 Braga, Portugal and the ICVS/3B's-PT Government A
  • Booty MG; 1] Department of Microbiology and Physiological Systems, University of Massachusetts Medical School, Worcester, Massachusetts 01655, USA. [2] Program in Immunology, Division of Medical Sciences, Harvard Medical School, Boston, Massachusetts 02115, USA.
  • Carpenter SM; 1] Department of Microbiology and Physiological Systems, University of Massachusetts Medical School, Worcester, Massachusetts 01655, USA. [2] Division of Infectious Disease, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.
  • Jayaraman P; Department of Microbiology and Physiological Systems, University of Massachusetts Medical School, Worcester, Massachusetts 01655, USA.
  • Rothchild AC; 1] Department of Microbiology and Physiological Systems, University of Massachusetts Medical School, Worcester, Massachusetts 01655, USA. [2] Program in Immunology, Division of Medical Sciences, Harvard Medical School, Boston, Massachusetts 02115, USA.
  • Behar SM; Department of Microbiology and Physiological Systems, University of Massachusetts Medical School, Worcester, Massachusetts 01655, USA.
Nat Rev Microbiol ; 12(4): 289-99, 2014 04.
Article in En | MEDLINE | ID: mdl-24590243
ABSTRACT
Clinical trials of vaccines against Mycobacterium tuberculosis are well under way and results are starting to come in. Some of these results are not so encouraging, as exemplified by the latest Aeras-422 and MVA85A trials. Other than empirically determining whether a vaccine reduces the number of cases of active tuberculosis, which is a daunting prospect given the chronic nature of the disease, we have no way of assessing vaccine efficacy. Therefore, investigators seek to identify biomarkers that predict vaccine efficacy. Historically, focus has been on the production of interferon-γ by CD4(+) T cells, but this has not been a useful correlate of vaccine-induced protection. In this Opinion article, we discuss recent advances in our understanding of the immune control of M. tuberculosis and how this knowledge could be used for vaccine design and evaluation.
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Tuberculosis / Tuberculosis Vaccines / Mycobacterium tuberculosis Type of study: Prognostic_studies Limits: Humans Language: En Journal: Nat Rev Microbiol Journal subject: MICROBIOLOGIA Year: 2014 Document type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Tuberculosis / Tuberculosis Vaccines / Mycobacterium tuberculosis Type of study: Prognostic_studies Limits: Humans Language: En Journal: Nat Rev Microbiol Journal subject: MICROBIOLOGIA Year: 2014 Document type: Article